Nomura Shosaku, Taniura Takehito, Shouzu Akira, Omoto Seitaro, Suzuki Masahiko, Okuda Yoshinori, Ito Tomoki
First Department of Internal Medicine, Kansai Medical University, Hirakata,
Division of Internal Medicine, Daiwa Hospital, Suita.
Vasc Health Risk Manag. 2018 Sep 18;14:225-232. doi: 10.2147/VHRM.S171143. eCollection 2018.
The aim was to evaluate the significance of arteriosclerosis obliterans-related biomarkers in patients with type 2 diabetes mellitus (T2DM), and to compare the effects of sarpogrelate, eicosapentaenoic acid (EPA) and pitavastatin on these markers.
Seventy-two arteriosclerosis obliterans patients with T2DM were classified into two groups, pitavastatin with either sarpogrelate (PS) or EPA (PE). We observed no differences in all biomarkers between the PS and PE groups before treatments.
The levels of body mass index, hemoglobin A1c, soluble E-selectin, soluble vascular cell adhesion molecule 1, plasminogen activator inhibitor-1 and platelet-derived microparticle in the PE group decreased significantly after treatment. The ankle branchial pressure index and adiponectin levels significantly increased in the PE group after treatment compared with the PS group.
These results suggest that combination therapy using pitavastatin and EPA possesses an antiatherosclerotic effect and may be beneficial for prevention of vascular complications in patients with T2DM.
目的是评估2型糖尿病(T2DM)患者中与闭塞性动脉硬化相关生物标志物的意义,并比较沙格雷酯、二十碳五烯酸(EPA)和匹伐他汀对这些标志物的影响。
72例合并闭塞性动脉硬化的T2DM患者被分为两组,分别接受匹伐他汀联合沙格雷酯(PS组)或匹伐他汀联合EPA(PE组)治疗。治疗前,PS组和PE组的所有生物标志物均无差异。
PE组治疗后体重指数、糖化血红蛋白、可溶性E选择素、可溶性血管细胞黏附分子1、纤溶酶原激活物抑制剂-1和血小板衍生微粒水平显著降低。与PS组相比,PE组治疗后踝臂压力指数和脂联素水平显著升高。
这些结果表明,匹伐他汀与EPA联合治疗具有抗动脉粥样硬化作用,可能有助于预防T2DM患者的血管并发症。